STAAR Surgical Company reports developments in lens-based refractive surgery through its EVO family of Implantable Collamer® Lenses, including EVO ICL™ for vision correction. The company designs, manufactures and sells implantable lenses for the eye and related delivery systems, with ICL products forming the core of its revenue base.
Recurring updates cover quarterly and annual results, preliminary sales, strategic-plan progress, market trends in China, the Americas and other international markets, regulatory indication changes, clinical evidence for EVO ICL, product adoption milestones, board and executive transitions, and shareholder voting or governance matters.
STAAR Surgical (STAA) authorized a share repurchase program of up to $50 million on September 24, 2026. The company may buy outstanding common shares but is not required to purchase any set number. The program is expected to continue for the next twelve months unless the board extends or shortens it. STAAR will decide the timing, price, method and amount of any purchases, subject to market conditions, legal requirements and other considerations.
STAAR intends to fund repurchases with organic free cash flow and cash on hand. It held $181.5 million in cash, cash equivalents and available-for-sale investments and had no outstanding debt as of July 3, 2026. Approximately 50.1 million common shares were outstanding as of August 7, 2026. The program may be modified, suspended or discontinued without prior notice. Management said the authorization reflects its view that STAAR shares are undervalued.
STAAR Surgical (STAA) released a global report, “The Future of Refractive Surgery”, showing a structural shift from laser-based to lens-based vision correction across seven major markets.
Across all regions surveyed, excimer laser procedure volumes have declined or stagnated, while phakic IOL adoption has risen. In the United States, laser procedure volume has fallen 52% since 2022, while EVO ICL™ adoption has increased 76%, more than tripling its market share. A consumer survey of 7,800 people found that 80% want to be free of glasses and contacts, 58% prefer a reversible option, and 59% are not open to laser correction, with safety and procedure fears outweighing cost barriers.
The report highlights advanced lens-based adoption in Asia, expanding label indications for EVO ICL in Brazil and the U.S., and projects long-term tailwinds from rising global high myopia.
STAAR Surgical (STAA) has appointed former President and CEO David Bailey as Chief Commercial Officer, reporting to current President and CEO Warren Foust.
Bailey rejoins the executive committee to lead the next commercial phase for EVO Implantable Collamer Lens (EVO ICL), which the company describes as gaining share as laser refractive procedures stagnate or decline globally. During his earlier leadership at STAAR, Bailey helped pivot the business toward phakic IOL-based refractive surgery, raised more than $60 million, secured FDA approval of the ICL in 2005, expanded commercial launches across Asia, and acquired STAAR’s former Canon joint venture in Japan to gain exclusive control of patents and technology.
By the end of his prior tenure, international revenue accounted for 74% of global sales and ICL revenue reached approximately $32 million, a figure the company notes has since grown more than tenfold.
STAAR Surgical (STAA) appointed Ben Park, Ph.D., as Chief Technology Officer, joining the Executive Committee and reporting to President and CEO Warren Foust.
The company links this hire to its strategy to evolve from a single‑product focus around EVO Implantable Collamer Lenses to a multi‑product innovation platform. STAAR highlights ongoing R&D and Advanced Research efforts preparing for first‑in‑human studies of next‑generation products and positions Park to accelerate its innovation roadmap and use of proprietary Collamer technology. Park previously led emerging technology at Align Technology and has held senior roles at Fingertips Lab, Volcano Corporation, and Fluid Medical.
STAAR Surgical (NASDAQ: STAA) reported second quarter 2026 net sales of $93.5 million, up 111% year over year, with net income of $8.1 million or $0.16 per diluted share, versus a loss a year ago. Adjusted EBITDA was $20.0 million, or $0.39 per diluted share, and gross margin improved to 74.5%.
China generated $52.3 million of sales (over 50% of revenue), growing more than 100% year over year and 10% sequentially, while net sales excluding China were $41.2 million, up 6%. APAC sales rose 189% year over year, Americas grew 12%, and EMEA declined slightly but grew 12% excluding the Middle East. Cash, cash equivalents and investments reached $181.5 million at quarter-end, up from $163.9 million at the end of Q1 2026.
STAAR Surgical (NASDAQ: STAA) announced that its Board appointed Warren Foust as President, Chief Executive Officer and Board member, effective August 4, 2026, following a global search. Foust has been President and COO since March 2025 and Interim Co-CEO since February 2026.
Deborah Andrews, Interim Co-CEO since February 2026, will become Executive Vice President while continuing as Chief Financial Officer. According to STAAR Surgical, the company has just completed the strongest first half in its history, with robust year-over-year growth, increasing profitability, accelerating market share momentum, and sequential growth in China without inventory buildup.
STAAR Surgical (NASDAQ: STAA) will release its second quarter 2026 financial results and a shareholder letter for the quarter ended July 3, 2026, on Wednesday, August 12, 2026, after market close, followed by an earnings webcast and conference call at 5:30 p.m. ET / 2:30 p.m. PT.
Management will review financial results, operational execution, and strategic priorities, including revenue growth, profit expansion, innovation initiatives, and market dynamics in key regions such as China and the United States. The live webcast and a replay (available for at least 90 days) can be accessed via the provided Chorus Call link or the STAAR Surgical investor relations website.
STAAR Surgical (NASDAQ: STAA) announced unaudited preliminary Q2 2026 net sales expected to exceed $90 million, compared with $44.3 million in Q2 2025, more than doubling year over year. Final results are expected on August 12, 2026.
According to STAAR Surgical, growth was driven by sequential improvement in China, solid performance across Asia-Pacific, and double-digit percentage growth in the Americas. In EMEA, reported net sales declined by a low single-digit percentage due to turmoil in the Middle East, but EMEA excluding the Middle East delivered double-digit percentage growth.
The company noted ongoing geopolitical and macroeconomic headwinds in the Middle East and parts of EMEA and Asia-Pacific that continue to pressure sales and could affect future growth if they persist or broaden. STAAR also cited operational challenges from an ERP system implementation but expects to resolve remaining system issues in Q3 2026.
Distributor inventories for EVO ICLs in China, which constrained net sales in Q2 2025, now appear within the company’s targeted range. The preliminary figures remain subject to adjustment as quarterly review procedures and auditor review are completed.
STAAR Surgical (NASDAQ: STAA) announced management participation in two upcoming virtual investor events: the Stifel 2026 Virtual Ophthalmology Forum on May 26, 2026, and a Canaccord Genuity Virtual Fireside Chat on May 27, 2026.
Live and archived webcasts will be accessible via STAAR’s investor relations website.
STAAR Surgical (NASDAQ: STAA) reported record first-quarter 2026 net sales of $93.5 million, up 119.6% year over year, with net sales excluding China up 6% to $46.1 million. Gross margin rose to 73.6%. The company posted net income of $5.2 million ($0.10 GAAP EPS) versus a prior-year loss and Adjusted EBITDA of $24.4 million ($0.48 per diluted share). Operating expenses fell to $60.9 million, or $51.5 million excluding restructuring and merger costs. Cash, cash equivalents, and investments were $163.9 million with no debt. Growth was driven by China’s recovery, double-digit U.S. net sales growth above $6 million, and early demand for EVO+ ICL in China.